IgA nephropathy

GLASGOW, Scotland – June 6, 2026 AstraZeneca’s rare disease division, Alexion, has reported positive interim Phase III results for...

WELLESLEY HILLS, Mass., June 5, 2026 Climb Bio, Inc. announced the presentation of initial Phase 1 safety data and...

MUMBAI, India, June 2, 2026 Alkem Laboratories has announced the launch of India’s first semaglutide single-shot pre-filled syringes, marking...

GLASGOW, Scotland, June 4, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. have announced positive...

BOSTON, June 1, 2026 Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics...

Cambridge, United Kingdom – April 21, 2026 AstraZeneca announced that its complement inhibitor Ultomiris® (ravulizumab) achieved statistically significant and...

Cambridge, Massachusetts & Hangzhou, China, April 20, 2026 In a significant strategic move within the biopharmaceutical industry, Biogen Inc....

San Diego, California | April 13, 2026 Travere Therapeutics, Inc. has announced that the U.S. Food and Drug Administration...

Tokyo, Japan, November 26 2025 — Renalys Pharma has announced positive topline results from its Phase III clinical study...

BASEL, Oct. 16, 2025 — Novartis announced positive final Phase III results from its APPLAUSE-IgAN trial, confirming that Fabhalta®...